Rapid Plasma Reagin Test Market

Rapid Plasma Reagin Test Market Outlook

The rapid plasma reagin test market is likely to register a CAGR of 4% during the forecast period, and is anticipated to reach a market share of US$ 68.51 Mn in 2032, from US$ 46.28 Mn in 2022, owing to the growing demand for the rapid testing to reduce time consumption and need of instruments.

One of the most common sexually transmitted infections is syphilis. According to the World Health Organisation, around 5.6 million new cases of syphilis were reported worldwide in 2012 among adults and adolescents aged 15 to 49. This is one of the major factors for higher sales of rapid plasma reagin test.

The demand for rapid plasma reagin tests for early detection is increasing as a result of growing and non-profit organizations' initiatives to alleviate the burden of sexually transmitted illnesses. Syphilis can be cured if caught early enough; this emphasizes the need for accurate and prompt diagnosis, which results in urgent demand for rapid plasma reagin test.

The rapid plasma reagin test market is being driven by an increase in the prevalence of syphilis, increased awareness of sexually transmitted diseases, technical advancements. Introduction of new products enhancing the sales of rapid plasma reagin test kits.

What are the Wins in the Rapid Plasma Reagin Test Market

The most common factor driving demand for rapid plasma reagin test solutions is the rising frequency of syphilis. The rapid plasma reagin test market is expected to develop due to rising demand for screening pregnant women for syphilis prevention in their children.

The sales of rapid plasma reagin test is growing due to rising demand for rapid testing to save time and reduce the requirement for instruments. The rapid plasma reagin test market is predicted to increase as a result of technological advancements and the introduction of new products.

The sales of rapid plasma reagin test is predicted to rise due to an increase in the number of healthcare testing programs and awareness campaigns for sexually transmitted diseases.

What are the Milestones in the Rapid Plasma Reagin Test Market

Low reimbursement rates for rapid plasma reagin test procedures are projected to limit the demand for rapid plasma reagin tests. In addition, limited awareness of sexually transmitted infections in the population of low and middle-income countries is projected to stymie the sales of rapid plasma reagin test kits.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What is the Regional Outlook of the Rapid Plasma Reagin Test Market

Due to the increased use of new technologies and rapid test kits for syphilis testing, North America is likely to lead the rapid plasma reagin test market. As laboratory-based rapid testing demand for sexually transmitted infection grows, Europe is predicted to generate the second-highest rapid plasma reagin test market revenue share in the rapid plasma reagin test.

The Asia Pacific rapid plasma reagin test market share is predicted to grow at a faster rate due to increased sexually transmitted infection (STI) awareness efforts and the rising prevalence of STI illnesses.

As a result of increased awareness of sexually transmitted infections (STIs) and government programs for diagnostic testing, Asian countries such as India and China are predicted to develop at the fastest rate, with the higher sales of rapid plasma reagin test over the forecast period.

How Competition Influences the Rapid Plasma Reagin Test Market

Some market participants in the global rapid plasma reagin test market across the value chain are Thermo Fisher Scientific, F. Hoffmann-La Roche AG, Beckman Coulter Inc (Danaher Corporation), Abbott Laboratories, Siemens AG, Sekisui Diagnostics, Immunostics Inc., Cardinal Health, Inc., Sclavo Diagnostics International, Novacyt Group, Meridian Bioscience Inc., Arlington Scientific, Inc., Bio-Rad Laboratories, Inc. and other companies. With novel product formulations and launches, these prominent industry players are expected to boost rapid plasma reagin test market share growth.

• Market competitors in the rapid plasma reagin test are working on releasing new products and kits that will allow them to test with more precision, and contribute to the greater sales of the rapid plasma reagin test. For example, Arlington Scientific Inc. received FDA approval for its ChemWell RPR automated analyzer for cost-effective syphilis diagnosis in September 2019.
• Rapid plasma reagin tests for early detection are in high demand due to the rising frequency of sexually transmitted infections (STIs) and growing awareness campaigns. The introduction of a novel diagnostic approach has influenced the rapid plasma reagin test market's growth.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Sign-Up

Report Scope